Lunai Bioworks Inc.
LNAINasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$189.0M | −$81.6M | −$38.6M | −$116.1M | −$23.4M | −$11.9M |
| Net income | −$178.0M | −$88.4M | −$39.7M | −$113.4M | −$26.7M | −$11.4M |
| Total assets | $8.2M | $163.1M | $58.3M | $84.6M | $189.6M | $178.1M |
| Total liabilities | $29.6M | $31.2M | $11.8M | $12.0M | $14.9M | $11.8M |
| Equity | −$21.3M | $132.0M | $46.5M | $72.6M | $174.7M | $166.3M |
| EPS (diluted) | $-1.08 | $-0.91 | $-0.71 | $-2.16 | — | — |
| Shares out. | 231.8M | 156.2M | 65.7M | 53.0M | 52.2M | 46.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 833.8%
- Return on assets
- −2162.7%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 359.4%
- Debt / equity
- —
- Book value / share
- $-0.09
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -379.62distress
- Accruals / assets
- −2067.0%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Feb 18, 2025
- NT 10-Kmissed a reporting deadline ↗Oct 1, 2024
- NT 10-Kmissed a reporting deadline ↗Sep 29, 2023
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2022
- NT 10-Kmissed a reporting deadline ↗Sep 29, 2022
- NT 10-Qmissed a reporting deadline ↗May 16, 2019
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- William Anderson WittekindActivist (13D)Dec 9, 2025
- Laksya Ventures Inc.Passive (13G)Sep 26, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.5M | 1.0 | +50.5% |
| Apr 30, 2026 | 1.7M | 1.0 | +112.2% |
| Apr 15, 2026 | 779,601 | 1.0 | -48.4% |
| Mar 31, 2026 | 1.5M | 1.0 | -50.3% |
| Mar 13, 2026 | 3.0M | 1.0 | +282.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 20, 2026
- Shareholder voteMay 13, 2026
- Entered a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Unregistered equity sale · Modified shareholder rights · Amended charter or bylawsMay 1, 2026
- Other material eventApr 28, 2026
- Entered a material agreement · Unregistered equity sale · Other material eventMar 30, 2026
- Other material eventMar 5, 2026
- Delisting / listing-standard noticeFeb 23, 2026
- Delisting / listing-standard notice · Regulation FD disclosureFeb 12, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KFORM 8-KMay 20, 2026
- 10-QFORM 10-QMay 15, 2026
- 8-KFORM 8-KMay 13, 2026
- 8-K/AFORM 8-K/AMay 11, 2026
- DEFR14AFORM DEFR14AMay 1, 2026
- 8-KFORM 8-KMay 1, 2026
- 8-KFORM 8-KApr 28, 2026
- DEFA14AFORM DEFA14AApr 28, 2026
- DEFR14AFORM DEFR14AApr 15, 2026
- DEF 14AFORM DEF 14AApr 13, 2026
- PRE 14AFORM PRE 14AApr 2, 2026
- 8-KFORM 8-KMar 30, 2026
- 8-KFORM 8-KMar 5, 2026
- 8-KFORM 8-KFeb 23, 2026
- 10-QFORM 10-QFeb 17, 2026